2.13
-0.02(-0.93%)
Currency In USD
| Previous Close | 2.15 |
| Open | 2.15 |
| Day High | 2.16 |
| Day Low | 2.11 |
| 52-Week High | 4.98 |
| 52-Week Low | 1.15 |
| Volume | 298,813 |
| Average Volume | 1.13M |
| Market Cap | 102.9M |
| PE | -0.96 |
| EPS | -2.22 |
| Moving Average 50 Days | 2.69 |
| Moving Average 200 Days | 2.42 |
| Change | -0.02 |
If you invested $1000 in Cassava Sciences, Inc. (SAVA) 10 years ago, it would be worth $1,298.78 as of January 16, 2026 at a share price of $2.13. Whereas If you bought $1000 worth of Cassava Sciences, Inc. (SAVA) shares 5 years ago, it would be worth $1,151.35 as of January 16, 2026 at a share price of $2.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
GlobeNewswire Inc.
Jan 13, 2026 1:00 PM GMT
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety pro
Cassava Announces Agreement to Settle Securities Class Action Litigation
GlobeNewswire Inc.
Dec 23, 2025 1:00 PM GMT
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tub
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
GlobeNewswire Inc.
Oct 22, 2025 12:00 PM GMT
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tub